
The Washington Post @washingtonpost
A pharmaceutical company formerly owned by Martin Shkreli will pay as much as $40 million to resolve price-gouging allegations brought by federal regulators and seven states. https://t.co/iWWhVcK6u2 — PolitiTweet.org